- Report
- September 2023
- 170 Pages
Global
From €1913EUR$1,990USD£1,642GBP
- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- January 2024
- 200 Pages
Global
From €3990EUR$4,150USD£3,423GBP
- Report
- October 2023
- 145 Pages
Global
From €3029EUR$3,150USD£2,598GBP
- Report
- November 2023
- 147 Pages
Global
From €2404EUR$2,500USD£2,062GBP
- Report
- August 2022
- 117 Pages
Global
From €4567EUR$4,750USD£3,918GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3125EUR$3,250USD£2,681GBP
- Report
- August 2022
- 115 Pages
Global
From €4159EUR$4,325USD£3,568GBP
- Report
- January 2021
- 32 Pages
Global
€1267EUR$1,318USD£1,087GBP
- Report
- June 2021
- 55 Pages
Global
From €6726EUR$6,995USD£5,770GBP
- Report
- January 2019
- 35 Pages
Global
From €962EUR$1,000USD£825GBP
Ingrezza is a Central Nervous System (CNS) drug used to treat adults with tardive dyskinesia, a neurological disorder characterized by involuntary, repetitive movements. It is the first and only FDA-approved treatment for this condition. Ingrezza works by blocking the dopamine receptor, which is thought to be responsible for the abnormal movements associated with tardive dyskinesia.
The Ingrezza market is composed of pharmaceutical companies that manufacture and distribute the drug. These companies are responsible for researching, developing, and marketing the drug to healthcare providers and patients. They also provide support services such as patient education and reimbursement assistance.
Some companies in the Ingrezza market include Neurocrine Biosciences, Inc., Teva Pharmaceuticals, and Mylan N.V. Show Less Read more
